Treatment of Inflammatory Bowel Disease with Biologics
154 withdrawal after a median of 7.5 months to 2 years of treatment. Despite this, 21–45% of patients relapsed at 1 year [ 41 ...
155 anti-TNF-α therapy withdrawal, and to quote Ben-Horin, “[This] illustrates[s] the need for careful and case-by-case interpre ...
156 No recommendation was made for fistulizing CD. There is currently no recommen- dation on the minimal duration of remission f ...
157 Summary Based on the current literature, withdrawal of anti-TNF-α therapy is possible in highly selected patients who are in ...
158 Allez M, Lémann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol ...
159 Seiderer J, Göke B, Ochsenkühn T. Safety aspects of infliximab in inflammatory bowel dis- ease patients: a retrospective co ...
160 Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor α therapy in inflamma- tory bowel disease. World J Gas ...
161 Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, et al. Infliximab as a bridge to remission main ...
162 Muñoz Villafranca C, Bravo Rodríguez MT, Ortiz de Zárate J, Arreba González P, García Kamiruaga I, Heras Martín J, et al. ...
© Springer International Publishing AG 2018 163 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
16 4 infliximab, with these patients having excellent response rates. Kugathasan et al. reported outcomes of 15 consecutive chi ...
165 infusion study group. At week 60, 61% of patients on episodic infliximab therapy were in remission compared to 83% of patien ...
166 by PGA; by 2 years, 21% of patients had mild disease and 67% had inactive disease; and at 3 years of maintenance therapy, 30 ...
167 with 73% having response at 10 weeks (after completion of induction dosing), and the proportion of patients responding after ...
168 were receiving concomitant mercaptopurine. A larger single-center retrospective series by McGinnis et al. evaluated the shor ...
169 severe colitis showed that response to infliximab may decrease with time, and dose escalation in this population was commonl ...
170 et al. evaluated the response on adalimumab therapy of ten patients (seven CD, three UC) previously treated with infliximab, ...
171 1 study, a multicenter randomized trial, evaluated the safety and efficacy of adali- mumab in pediatric CD [ 36 ]. Similar t ...
172 off-label as a second-line biological therapy in refractory pediatric UC. An early report by Noe et al. evaluated the short ...
173 symptomatic remission also had more substantial improvement in linear growth compared to those who only had a partial clinic ...
«
4
5
6
7
8
9
10
11
12
13
»
Free download pdf